# US 2026/0000693 A1 · Serotonergic psychedelic agent for treating selective mutism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0000693 A1
- Document ID: US20260000693A1
- Status: Published application
- Kind: A1
- Application number: 18/992,686
- Filed: 2023-07-12
- Published: 2026-01-01
- Earliest claimed: 2022-07-19
- Assignees: Lobe Sciences Ltd.
- Applicants: Lobe Sciences Ltd.
- Inventors: Lyl TOMLINSON; Frederick SANCILIO; Maghsoud DARIANI
- Web page: https://patentgrep.com/patent/US20260000693A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for treating or alleviating symptoms of selective mutism in a human subject with a serotonergic psychedelic agent alone or in combination with N-acetylcysteine are provided.

## Claims

### Claim 1

A method for alleviating one or more symptoms of selective mutism (SM) in a human, said method comprising administering to a human suffering from SM a serotonergic psychedelic agent.

### Claim 2 (depends on 1)

The method of claim 1 wherein the serotonergic psychedelic agent is a psilocibe-derived agent.

### Claim 3 (depends on 2)

The method of claim 2 wherein the psilocibe-derived agent is psilocybin or psilocin or a salt, conjugate or ester thereof.

### Claim 4 (depends on 1)

The method of claim 1 further comprising administering to the human N-acetylcysteine (NAC).

### Claim 5 (depends on 1)

The method of claim 1 wherein the human is a child suffering from SM.

### Claim 6 (depends on 1)

The method of claim 1 wherein one or more behaviors associated with SM is selected from a persistent failure to speak in select social contexts, reliance on non-verbal cues in lieu of talking, fear of social embarrassment, social isolation and withdrawal, clinging, compulsive traits, negativism, temper tantrums, and mild oppositional behavior is decreased.

### Claim 7

A composition comprising a serotonergic psychedelic agent in an amount effective in alleviating one or more symptoms of SM.

### Claim 8 (depends on 7)

The composition of claim 7 wherein the serotonergic psychedelic agent is a psilocibe-derived agent.

### Claim 9 (depends on 8)

The composition of claim 8 wherein the psilocibe-derived agent is psilocybin or psilocin or a salt, conjugate or ester thereof.

### Claim 10 (depends on 7)

The composition claim 7 further comprising human N-acetylcysteine (NAC).

### Claim 11 (depends on 7)

The composition of claim 7 formulated for administration to a child suffering from SM.
